Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development – The BioCentury Show

Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational middle.” In a wide-ranging interview on The BioCentury Show with BioCentury Washington Editor Steve Usdin, Knudsen discussed the Parker Institute’s focus on accelerating the path from scientific breakthrough to medical impact. As it approaches its tenth anniversary, the institute has deployed about $400 million, catalyzing r...

Poddgruvan

Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development

Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking

Ep. 112 - Chris Arendt on rebuilding Takeda for AI

Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner

Ep. 110 - Richard Pops on Three Decades in Biotech: Drug pricing, FDA and China

Ep. 108 - Rethinking Discovery: Chris Hollowood on Causal Biology and Syncona’s Strategy

Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing

Ep. 106 - Can the U.K. Capture Biotech Value? Daniel Mahony on Growth, Pricing and Reform

Ep. 105 - Recursion’s Najat Khan: AI Will Be Judged by the Medicines It Delivers

Ep. 104 - SoftBank’s Jacqueline Fok on AI Drug Development, Metsera and the U.K. Biotech Opportunity

Ep. 103 - Kolchinsky: FDA Conservatism, MFN and IRA Are Slowing Drug Development